Harvard spinout GRO Biosciences has a platform technology for engineering therapeutic proteins that won’t prompt an immune response against them. The startup’s lead program is a potential competitor to an Amgen gout drug acquired in a multi-billion dollar deal.
Harvard University spinout GRO Biosciences has technology offering the potential for protein therapies that are safer and more effective than currently available biologic drugs. The startup's research is now backed by $25 million, a Series A financing round whose investors include the venture arm of Bayer.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.